Literature DB >> 2554114

Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.

R P Mason1, S F Campbell, S D Wang, L G Herbette.   

Abstract

The distinctive pharmacokinetic and pharmacodynamic activity of amlodipine, including long onset and duration of activity as a calcium channel antagonist, may be related to its interactions with membranes. We have used X-ray crystallography and small-angle X-ray scattering to examine and compare the crystal structure of amlodipine and its location in cardiac sarcolemmal lipid bilayers with that of uncharged dihydropyridines (DHPs) such as nimodipine. Crystallographic analysis demonstrated that the DHP ring of amlodipine is considerably more planar than that of nimodipine, that amlodipine has a greater torsion angle between the DHP and aryl rings, and that the protonated amino group extends away from the DHP ring structure. Despite the positive charge of amlodipine at physiological pH, membrane electron density profile structures showed amlodipine to have a time-averaged location near the hydrocarbon core/water interface similar to that observed for several uncharged DHPs. However, unlike uncharged DHPs, this location is consistent with an ionic interaction between the protonated amino function of amlodipine and the negatively charged phospholipid headgroup region, in addition to a hydrophobic interaction with the fatty acyl chain region near the glycerol backbone similar to other DHPs. This location may also provide an appropriate conformation and orientation for amlodipine binding to its receptor site at this depth in the membrane. Finally, we have measured the nonspecific partitioning of amlodipine into native sarcoplasmic reticulum membranes from rabbit skeletal muscle and compared these data with those for the uncharged DHPs. The partition coefficient into light sarcoplasmic reticulum for amlodipine was higher than that observed for most uncharged DHPs and rates of incorporation of amlodipine into membranes were very high, as with other DHPs, whereas the "washout time" of amlodipine from these membranes was longer by over 1 order of magnitude. These data suggest differences in membrane interactions for amlodipine, compared with uncharged DHPs, that may be correlated with its novel pharmacodynamic and pharmacokinetic profile.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554114

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Potentiation of cardiodepressive action among calcium antagonists from different classes: evidence for a mechanism at the single calcium channel level.

Authors:  S Braun; N Frey; S Herzig; C Hilbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

2.  L-type calcium channel blockers and Parkinson disease in Denmark.

Authors:  Beate Ritz; Shannon L Rhodes; Lei Qian; Eva Schernhammer; Jørgen H Olsen; Søren Friis
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

3.  Binding constants determined from Ca2+ current responses to rapid applications and washouts of nifedipine in frog cardiac myocytes.

Authors:  P F Méry; L Hove-Madsen; J L Mazet; R Hanf; R Fischmeister
Journal:  J Physiol       Date:  1996-07-01       Impact factor: 5.182

4.  The thermodynamics of the partitioning of ionizing molecules between aqueous buffers and phospholipid membranes.

Authors:  Rupert P Austin; Patrick Barton; Andrew M Davis; Roger E Fessey; Mark C Wenlock
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

5.  Barnidipine block of L-type Ca(2+) channel currents in rat ventricular cardiomyocytes.

Authors:  J W Wegener; H Meyrer; J Rupp; H Nawrath
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 6.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine.

Authors:  Mark B Kahn; Kathleen Boesze-Battaglia; David W Stepp; Artium Petrov; Yong Huang; R Preston Mason; Thomas N Tulenko
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09-23       Impact factor: 4.733

Review 8.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

9.  Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning.

Authors:  G A Sawada; N F Ho; L R Williams; C L Barsuhn; T J Raub
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

10.  Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts.

Authors:  Nina S Ghais; Yanmin Zhang; Andrew A Grace; Christopher L-H Huang
Journal:  Exp Physiol       Date:  2008-10-31       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.